BACKGROUND: Castration-resistant prostate cancer (CRPC) is a near uniformly fatal form of prostate cancer; however, information on time to development and predictors for progression to CRPC is limited.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
We report a detailed longitudinal study for development of CRPC in men initially treated with external beam radiotherapy (EBRT).
METHODS: During 1991-2008, 2,478 patients with clinically localized prostate cancer were treated with dose-escalated EBRT at a single institution. The primary objective was to determine predictors of CRPC among men who failed definitive EBRT and progressed to salvage androgen-deprivation therapy (ADT). CRPC was defined as castrate levels of testosterone (< 50 ng/dl) with progressive biochemical or radiographic disease.
RESULTS: For the entire cohort (n = 2,478), the 10-year cumulative incidence rate for developing CRPC was 9.9%. For those that progressed to salvage ADT (n = 362), the 7-year cumulative incidence rates for developing CRPC from time of salvage ADT was 33.7%. Amongst this cohort, multivariable analysis demonstrated that PSA doubling-time (continuous; hazard ratio [HR], 0.98 (0.97-0.99), P < 0.001), higher Gleason score (HR, 1.96 (1.12-3.43); P = 0.034), and duration of ADT at time of EBRT (continuous; HR, 1.02 (1.01-1.03); P = 0.007) were associated with development of CRPC.
CONCLUSIONS: This represents the first report of predictors of CRPC for patients treated with modern dose-escalated EBRT. We demonstrate that among the minority of patients not initially cured after EBRT, those treated with longer-course ADT have higher rates of resistance to the re-introduction of ADT. Future trials will need to test this subgroup with more aggressive or alternative forms of salvage therapies.
Spratt DE, Zumsteg ZS, Pei X, Romesser PB, Yamada J, Kollmeier MA, Woo K, Zhang Z, Zelefsky MJ. Are you the author?
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, New York.
Reference: Prostate. 2014 Oct 18. Epub ahead of print.